Therapeutic Targets: Modulation, Inhibition, and Activation

To Purchase this product, please visit

https://dev.store.wiley.com/en-au/Therapeutic+Targets%3A+Modulation%2C+Inhibition%2C+and+Activation-p-9780470587195

Therapeutic Targets: Modulation, Inhibition, and Activation

Luis M. Botana,Mabel Loza

Available on Wiley Online Library

Description

Providing insight into where the next generations of drugs are likely to emerge, this book describes the pharmacology of therapeutically undefined targets and potential applications. In some cases, there are no defined drugs to modulate some of the targets, and in other cases inhibition or activation will render different therapeutic uses. Chapters cover specific biochemical targets like kinases, phosphatases, phosphodiesterases, and potassium channels. Because different diseases can require their own targeting strategies, the book has chapters on the strategies for targeting Alzheimer's, diabetes, pain, and inflammation.

About the Author

Luis M. Botana was Director of the Department of Pharmacology at the University of Santiago de Compostela (USC), Director of the European Union Reference Laboratory for Marine Biotoxins, and scientific advisor to the drug company LCIFGA. The author of 200 papers and 15 patents, Dr. Botana is the editor of several other books, including Phycotoxins: Chemistry and Biochemistry, published by Wiley (2007).

Mabel Loza is Professor of Pharmacology at the University of Santiago de Compostela (USC). She created the USEF Drug Screening Platform, with more than ten years of experience in public and private mixed early drug discovery programs.

To Purchase this product, please visit

https://dev.store.wiley.com/en-au/Therapeutic+Targets%3A+Modulation%2C+Inhibition%2C+and+Activation-p-9780470587195